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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S191herpetic neuralgia (n¼5), severe pain (n¼3), scarring (n¼1),
and motor weakness (n¼1); 2 patients required hospitaliza-
tion and 3 patients developed disseminated zoster.
Conclusions: Our limited retrospective analysis suggests
a signiﬁcant reduction in rates of post auto-HCT rates of VZV
infection with extended 12month antiviral prophylaxis. VZV
infection is a signiﬁcant complication post auto-HCT, and
extended prophylaxis appears to be safe and effective in this
setting.
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We report 35 patients who received high dose melphalan
and autologous stem cell transplantation for systemic AL
amyloidosis. Between Sep. 2006 and Jul. 2012, 35 patients
with AL amyloidosis were transplanted at Japanese Red Cross
Medical Center. Characteristics of patients were shown as
follows: median age; 54 (range 39-70), M/F¼15/20, major
organ involvement; heart 13, kidney 19, others 3 (liver 1,
trachea 1, peripheral nerve 1), median melphalan dose; 128
(range 50-200) mg/m2, median infused CD34+ cells; 2.67
(range 1.17-11.26) x 106/kg. Out of 35 patients, 28 are alive
after median follow up of 18.7 (range 2-68) months and two
and four years estimated overall survival were 84.6% and
66.6%, respectively. Four patients died of heart failure and
other three patients died of either gastrointestinal bleeding,
bacteremia, or malignancy. Four year estimated survival of
patients with cardiac involvement is 46.2% and is signiﬁ-
cantly lower as compared with that with others (69.2%).
Serum albumin increased (average 21%) in patients survived
more than 12months after ASCT. Serum free light chain (FLC)
was measured before and after ASCT in 7 patients, and of
those, FLC rapidly decreased after ASCT in 5 patients. Patients
without cardiac involvement showed satisfactory survival
with improvement of clinical symptom and serum albumin.
Careful patient selection and experienced management are
important especially for patients with cardiac involvement.
Serum FLCmay be useful for evaluating effectiveness of ASCT
and also for early detection of relapse.155
Results of a Phase 2 Clinical Trial Testing the Efﬁcacy of
Plerixafor in Combination with Chemotherapy in the
Mobilization of Autologous Blood Hematopoietic
Progenitor Cells
Edmund K. Waller 1, Heather Renfroe Johnson 2, Neera Jagirdar 2
, Cynthia Gaylor 3, Carol Lipscomb 2, Christopher Flowers 2,
Jonathan Kaufman 2, H. Jean Khoury 2, Amelia Langston 2,
MaryJo Lechowicz 2, Sagar Lonial 2, Ajay Nooka 2, Rajni Sinha 2,
R. Donald Harvey 2. 1 Bone Marrow and Stem Cell Transplant
Program, Emory University, Atlanta, GA; 2 Emory University
Winship Cancer Institute, Atlanta, GA; 3 Emory University
Hospital, Atlanta, GA
Background: The use of plerixafor formobilization following
chemotherapy has not been extensively studied. We tested
the hypothesis that adding plerixafor to G-CSF after chemo-
therapywould increase the proportion of patientsmobilizing
the target number of hematopoietic progenitor cells in one
day to 75% from a historical value of 50%.Methods:Multiplemyeloma (MM) or lymphoma patients for
whom autologous stem cell transplantation was intended
were eligible. Patients were mobilized with chemotherapy
consisting of either cyclophosphamide (N¼16), DCEP (N¼1),
R-ICE (N¼10), CHOP (N¼2) or R-HyperCVAD (N¼5) with daily
administration of G-CSF at a dose of 10 mcg/kg/day starting
one day after the completion of chemotherapy. The per-
protocol plan was subcutaneous injection of 240 mcg/kg
plerixaforon theﬁrstdayonwhich theneutrophil countwas>
1500 cells/uL followed by apheresis the next day. G-CSF, pler-
ixafor and apheresis were repeated daily until 5 (lymphoma)
or 10 x 10E6 CD34+ cells/kg (myeloma) were collected.
Results: 17 MM and 28 lymphoma patients with a median
age of 57 (range 33-73) were enrolled. 33/45 subjects (76%)
collected the target number of CD34+ cells in one day. 12
subjects (7 MM and 5 lymphoma) with a median CD34+
count of 201 cells/uL began apheresis without plerixafor on
the ﬁrst day of monitoring and collected a median of 19 x
10E6 CD34+ cells/kg in one day. The remaining 33 patients
(10 MM and 23 lymphoma) received plerixafor with median
numbers of 30 CD34+ cells/uL, and 4100 neutrophils/uL that
increased to 95 CD34+ cells/uL and 24,799 neutrophils/uL the
next day. Plerixafor-treated subjects collected amedian of 7.8
x 10E6 CD34+ cells/kg; 22 (66%) collected the target number
in one day, while 6 (18%), 3 (9%), and 2 (6%) of the plerixafor-
treated subjects required 2, 3, or 4 days of apheresis,
respectively. Plerixafor was well tolerated, with 29 total AE,
and no SAE recorded during mobilization and/or apheresis.
Seven grade 3/4 AE were seen, including thrombocytopenia
(4), fatigue (1), anemia (1) and hypokalemia (1). 44/45
enrolled subjects underwent high-dose chemotherapy and
re-infusion of CD34+ cells. Plerixafor-treated and non-pler-
ixafor treated transplant recipients promptly engrafted with
neutrophil and platelets at median of 12 and 16 days,
respectively, with stable hematopoiesis noted at 12 months.
Conclusions: Plerixafor administration after chemotherapy
for ASC mobilization is feasible and well tolerated. A greater
percentage (76%) of enrolled subjects collected more than
the target number of cells in one day of apheresis compared
with a historical cohort of patients mobilized with G-CSF
after chemotherapy (54%; P < 0.03). Daily monitoring of
blood counts after chemotherapy is needed to appropriately
schedule plerixafor administration. One-fourth of chemo-
therapy-treated patients mobilized an adequate number of
CD34+ in one day without plerixafor.156
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Bone marrow is a highly innervated tissue with nerve ﬁbers
terminating in association with stromal cells. Bone marrow
neuropathy has been associated with abnormal hematopoi-
etic stem cell (HSC) trafﬁcking and activity in animal models
of diabetes. There is also evidence that granulocyte colony-
stimulating factor (G-CSF) mediates its mobilizing effect on
HSC through modulation of norepinephrine release from
adrenergic neurons. Therefore, we hypothesized that pre-
